Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | FASN | P49327 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657231 | 0.85 | HPGDS (0.52) | HPGDSKMT2ABRD4NAMPTCYP2D6 | |
| SCHEMBL17758504 | 0.85 | HPGDS (0.52) | HPGDSKMT2ABRD4NAMPTCYP2D6 | |
| SCHEMBL17758514 | 0.85 | MAPK14 (0.56) | HPGDSKMT2ATAS1R3TAS1R1HRH3 | |
| SCHEMBL12825175 | 0.84 | HPGDS (0.53) | HPGDSKMT2ABRD4NAMPTCYP2D6 | |
| SCHEMBL13175758 | 0.84 | HPGDS (0.53) | HPGDSKMT2ABRD4NAMPTCYP2D6 | |
| SCHEMBL13175969 | 0.84 | HPGDS (0.53) | HPGDSKMT2ABRD4NAMPTCYP2D6 | |
| SCHEMBL17758478 | 0.83 | KMT2A (0.56) | KMT2ATAS1R3TAS1R1CYP2D6CYP2C9 | |
| SCHEMBL14093944 | 0.79 | KMT2A (0.54) | HPGDSKMT2ABRD4KDM1A | |
| SCHEMBL15651273 | 0.78 | KMT2A (0.49) | HPGDSKMT2ABRD4NAMPTCYP2D6 | |
| SCHEMBL27962669 | 0.78 | KMT2A (0.65) | HPGDSKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | HPGDS 2228/4885KMT2A 126/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.